Hartford HealthCare professional discusses weight loss drug approved by FDA to combat obesity

Good Morning CT at Nine

(WTNH) — FDA approved a weight loss drug to fight the ongoing battle against obesity. According to the Centers for Disease Control and Prevention, 42.4% of all adults in the U.S. suffer from obesity.

Director of Metabolic and Bariatric Surgery at Hartford Healthcare St. Vincent’s Medical Center Dr. Craig Floch breaks down how Semaglutide may be a potential game changer.

Semaglutide is an injectable drug made by the pharmaceutical company Novo Nordisk. The drug targets patients with a BMI over 30, or a BMI over 27.

Semaglutide was approved in 2019 by the FDA to treat Type 2 diabetes. To learn more about surgical and non-surgical options for weight loss go to myweightisover.com.

Copyright 2021 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Hartford

State issues health alert related to Delta variant

News /

Connecticut Science Center re-instates mask policy for visitors, staff ages 2 and older regardless of vaccination status

News /

New law restores state benefits to CT service members discharged due to LGBTQ+ status

News /

Gil emcees the Connecticut Veterans Hall of Fame Ceremony in Hartford

News /

Hartford police investigating shooting on Elliott Street that left one dead, one injured

News /

College students head out into CT communities with substantial COVID transmission to spread word about vaccines

News /
More Hartford

Trending Stories

Don't Miss

More Don't Miss